Compare DFLI & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFLI | JAGX |
|---|---|---|
| Founded | 2020 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 4.4M |
| IPO Year | 2021 | 2014 |
| Metric | DFLI | JAGX |
|---|---|---|
| Price | $2.32 | $2.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 253.6K | ★ 2.0M |
| Earning Date | 11-13-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,630,000.00 | $11,511,000.00 |
| Revenue This Year | N/A | $77.78 |
| Revenue Next Year | $61.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.77 | N/A |
| 52 Week Low | $0.41 | $0.20 |
| 52 Week High | $5.15 | $41.53 |
| Indicator | DFLI | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 45.70 |
| Support Level | $1.85 | $2.12 |
| Resistance Level | $2.88 | $3.07 |
| Average True Range (ATR) | 0.26 | 0.52 |
| MACD | 0.02 | -0.40 |
| Stochastic Oscillator | 53.67 | 10.58 |
Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.